Children with intracranial ependymomas have relatively poor outcomes despite the low-grade histology of these tumors and recent advances in diagnosis, microneurosurgical resection, and adjuvant therapy. Aggressive surgical resection and postoperative adjuvant therapy result in only a 5-year survival rate of 50%. In this paper, we provide a review of the current technical aspects of surgical resection, and focus on recent studies of the epidemiology, molecular markers, prognostic factors and adjuvant therapy for childhood intracranial ependymomas and discuss their implications for current and future management strategies.

Keywords:
Ependymoma, Children, Brain tumor, Review, Surgery
1.
Dohrmann G, Farwell J, Flannery J: Ependymomas and ependymoblastomas in children. J Neurosurg 1976;45:273.
2.
Barone B, Elvidge A: Ependymomas. A clinical study. J Neurosurg 1970;33:428–438.
3.
Becker L, Halliday W: Central nervous system tumors of childhood. Perspect Pediatr Pathol 1987;10:86–134.
4.
Coulon R, Till K: Intracranial ependymomas in children: A review of 43 cases. Childs Brain 1977;3:154–168.
5.
Dorhmann G: Ependymomas; in Wilkins R, Rengachary S (eds): Neurosurgery. New York, McGraw-Hill, 1985, pp 767–771.
6.
Duffner P, Cohen M: Treatment of brain tumors in babies and very young children. Pediatr Neurosci 1985;12:304–310.
7.
Duffner P, Cohen M, Myers M, Heise H: Survival of children with brain tumors: SEER Program, 1973–1980. Neurology 1986;36:597–601.
8.
Jellinger K: Pathology of human intracranial neoplasia; in Jellinger K (ed): Therapy of Malignant Brain Tumors. Wien, Springer, 1987, pp 1–90.
9.
Koos W, Miller M: Intracranial Tumors of Infants and Children. St Louis, Mosby, 1971, pp 331–334.
10.
Lejeune J, Dhellemmes P, Dupard T, et al: Les épendymomes intracrâniens. Expérience de 86 cas. Neurochirurgie 1987;33:118–123.
11.
Liebel S, Sheline G: Radiation therapy of neoplasms of the brain. J Neurosurg 1987;66:1–22.
12.
Liu H, Boggs J, Kidd J: Ependymomas in childhood. I. Histological survey and clinicopathological correlation. Childs Brain 1976;2:92–110.
13.
Matson D: Tumors of the posterior fossa; in Matson D (ed): Neurosurgery of Infancy and Childhood. Springfield, Thomas, 1969, pp 410–479.
14.
Nazar G, Hoffman H, Becker L, et al: Infratentorial ependymomas in childhood: Prognostic factors and treatment. J Neurosurg 1990;72:408–417.
15.
Oi S, Raimondi A: Ependymoma; in Pediatric Neurosurgery. New York, Grune & Stratton, 1979, pp 153–158.
16.
Pollack I: Current concepts: Brain tumors in children. N Engl J Med 1994;331:1500–1507.
17.
Russell D, Rubenstein L: Pathology of Tumors of the Nervous System. London, Arnold Press, 1977, pp 203–226.
18.
Svien H, Mabone R, Kernohan J, et al: Ependymoma of the brain: Pathologic aspects. Neurology 1953;3:1–15.
19.
Yates A, Becker L, Sachs L: Brain tumors in childhood. Childs Brain 1979;5:31–39.
20.
Young JJ, Miller R: Incidence of malignant tumors in US children. J Pediatr 1975;86:254–258.
21.
Hendrick E, Raffel C: Tumors of the fourth ventricle: Ependymomas, choroid plexus papillomas and dermoid cysts; in Pediatric Neurosurgery. Philadelphia, Saunders, 1989, pp 366–371.
22.
Ilgren E, Stiller C, Hughes J, et al: Ependymomas: A clinical and pathologic study. Clin Neuropathol 1984;3:113–121.
23.
Horn B, Heideman R, Geyer R, et al: A multi-institutional retrospective study of intracranial ependymoma in children: Identification of risk factors. J Pediatr Hematol Oncol 1999;21:203–211.
24.
Chiu J, Woo S, Ater J, et al: Intracranial ependymoma in children: Analysis of prognostic factors. J Neurooncol 1992;13:283–290.
25.
Perilongo G, Massimino M, Sotti G, et al: Analyses of prognostic factors in a retrospective review of 92 children with ependymoma: Italian Pediatric Neuro-Oncology Group. Med Pediatr Oncol 1997;29:79–85.
26.
Pollack I, Gerszten P, Martinez A, et al: Intracranial ependymomas of childhood: Long-term outcome and prognostic factors. Neurosurgery 1995;37:655–667.
27.
Rousseau P, Habrand J, Sarrazin D, et al: Treatment of intracranial ependymomas of children: Review of a 15-year experience. Int J Radiat Oncol Biol Phys 1994;28:381–386.
28.
Sutton L, Goldwein J, Perilongo G, et al: Prognostic factors in childhood ependymomas. Pediatr Neurosurg 1990–91;16:57–65.
29.
Kovalic J, Flaris N, Grigsby P: Intracranial ependymoma long-term outcome, patterns of failure. J Neurooncol 1993;15:125–131.
30.
Ernestus R, Wilcke O, Schroder R: Intracranial ependymomas: Prognostic aspects. Neurosurg Rev 1989;12:157–163.
31.
Wallner K, Wara W, Sheline G, Davis R: Intracranial ependymomas: Results of treatment with partial or whole brain irradiation without spinal irradiation. Int J Radiat Oncol Biol Phys 1986;12:1937–1941.
32.
Goldwein J, Laehy J, Packer R, et al: Intracranial ependymomas in children (abstract). Pediatr Neurosci 1988;14:148.
33.
Salazar O, Castro-Vita H, Van Houtte P, et al: Improved survival in cases of intracranial ependymoma after radiation therapy: Late report and recommendations. J Neurosurg 1983;59:652–659.
34.
Shaw E, Evans R, Scheithauer B, et al: Post-operative radiotherapy of intracranial ependymoma in pediatric and adult patients. Int J Radiat Oncol Biol Phys 1987;13:1457–1462.
35.
Berger M, Geyer J: Ependymomas of the fourth ventricle; in Cohen A (ed): Surgical Disorders of the Fourth Ventricle. London, Blackwell Science, 1996.
36.
Shuman R, Alvord E, Leech R: The biology of childhood ependymomas. Arch Neurol 1975;32:731–739.
37.
Duncan J, Hoffman H: Intracranial ependymomas; in Kaye A, Laws E (eds): Brain Tumors. New York, Churchill Livingstone, 1995, pp 493–504.
38.
Rubenstein L: Tumors of the central nervous system; in Atlas of Tumor Pathology, sect II, fasc 6. Washington, Armed Forces Institute of Pathology, 1972, pp 104–126.
39.
Kernohan J, Fletcher-Kernohan E: Ependymomas. A study of 109 cases. Res Publ Assoc Res Nerv Ment Dis 1937;16:182.
40.
Kernohan J, Sayre G: Tumors of the central nervous system; in Atlas of Tumor Pathology, sect X, fasc 35. Washington, Armed Forces Institute of Pathology, 1952, p 129.
41.
Kleiheus P, Burger P, Scheithauer B: World Health Organization: Histological Typing of Tumors of the Central Nervous System. New York, Springer, 1993.
42.
Woesler B, Moskopp D, Kuchelmeister K, et al: Intracranial metastasis of a spinal myxopapillary ependymoma: Case report. Neurosurg Rev 1998;21:62–65.
43.
Smyth M, Pitts L, Jackler R, Aldape K: Metastatic spinal ependymoma presenting as a vestibular schwannoma: Case illustration. J Neurosurg Spine 2000;92:247.
44.
Mork S, Loken A: Ependymoma. A follow-up study of 101 cases. Cancer 1977;40:907–915.
45.
Rorke L: Relationship of morphology of ependymoma in children to prognosis. Prog Exp Tumor Res 1987;30:170–174.
46.
Becker L: Ependymoblastoma; in Kleihues P, Cavenee W (eds): Pathology and Genetics of Tumours of the Nervous System. Lyon, International Agency for Research on Cancer, 1997, pp 94–95.
47.
Atlas S: Magnetic Resonance Imaging of the Brain and Spine. New York, Raven Press, 1991.
48.
Armington W, Osborn A, Cubberley D, et al: Supratentorial ependymoma: CT appearance. Radiology 1985;157:367–372.
49.
Spoto G, Press G, Hesselink J, Solomon M: Intracranial ependymoma and subependymoma: MR manifestations. AJNR 1990;11:83–91.
50.
Furie D, Provenzale J: Supratentorial ependymomas and subependymomas: CT and MR appearance. J Comput Assist Tomogr 1995;19:518–526.
51.
Courville C, Broussalian S: Plastic ependymomas of the lateral recess. Report of eight verified cases. J Neurosurg 1961;18:792.
52.
Fitz C, Rao K: Primary tumors in children; in Lee S, Rao K (eds): Cranial Computed Tomography and MRI. New York, McGraw-Hill, 1987, pp 365–412.
53.
Tortori-Donati P, Fondelli M, Cama A, et al: Ependymomas of the posterior cranial fossa: CT and MRI findings. Neuroradiology 1995;37:238–243.
54.
Carbone M, Rizzo P, Pass H: Simian virus 40, poliovaccines and human tumors: A review of recent developments. Oncogene 1997;15:1877–1888.
55.
Mortimer E, Lepow M, Gold E, et al: Long-term follow-up of persons inadvertently inoculated with SV40 as neonates. N Engl J Med 1981;305:1517–1518.
56.
Geissler E: SV40 and human brain tumors. Prog Med Virol 1990;37:211–222.
57.
Strickler H, Rosenberg P, Devesa S, et al: Contamination of poliovirus vaccines with simian virus 40 (1955–1963) and subsequent cancer rates. JAMA 1998:297:292–295.
58.
Bergsagel D, Finegold M, Butel J, et al: DNA sequences similar to those of simian virus 40 in ependymomas and choroid plexus tumors of childhood. N Engl J Med 1992;326:988–993.
59.
Lednicky J, Garcea R, Bergsagel D, Butel J: Natural simian virus 40 strains are present in human choroid plexus and ependymoma tumors. Virology 1995;212:710–717.
60.
Martini F, Iaccheri L, Lazzarin L, et al: SV40 early region and large T antigen in human brain tumors, peripheral blood cells, and sperm fluids from healthy individuals. Cancer Res 1996;56:4820–4825.
61.
Krainer M, Schenk T, Zielinski C, Muller C: Failure to confirm presence of SV40 sequences in human tumours. Eur J Cancer 1995;31A:1893.
62.
Kirschstein R, Gerger P: Ependymomas produced after intracerebral innoculation of SV40 into newborn hamsters. Nature 1962;195:299.
63.
Martuza R, Eldridge R: Neurofibromatosis 2 (bilateral acoustic neurofibromatosis). N Engl J Med 1988;318:684–688.
64.
Ransom D, Ritland S, Kimmel P, et al: Cytogenetic and loss of heterozygosity studies in ependymomas, pilocytic astrocytomas, and oligodendrogliomas. Genes Chromosomes Cancer 1992;5:348–356.
65.
James C, He J, Carlborn E, et al: Loss of genetic information in central nervous system tumors common to children and young adults. Genes Chromosomes Cancer 1990;2:94–102.
66.
Weremowicz S, Kupsky W, Morton C, Fletcher J: Cytogenetic evidence for a chromosome 22q tumor suppressor gene in ependymoma. Cancer Genet Cytogenet 1992;61:193–196.
67.
Nijssen P, Lekanne Deprez R, Tijssen C, et al: Familial anaplastic ependymoma: Evidence of loss of chromosome 22 in tumour cells. J Neurol Neurosurg Psychiatry 1994;57:1245–1248.
68.
Rubio M, Correa K, Ramesh V, et al: Analysis of the Neurofibromatosis 2 gene in human ependymomas and astrocytomas. Cancer Res 1994;54:45–47.
69.
Bijlsma E, Voesten A, Bijleveld E, et al: Molecular analysis of genetic changes in ependymomas. Genes Chromosomes Cancer 1995;13:272–277.
70.
Neuman E, Kalousek D, Norman M, et al: Cytogenetic analysis of 109 pediatric central nervous system tumors. Cancer Genet Cytogenet 1993;71:40–49.
71.
Sawyer J, Sammartino G, Husain M, et al: Chromosome aberrations in four ependymomas. Cancer Genet Cytogenet 1994;74:132–138.
72.
Sainati L, Bolcato S, Montaldi A, et al: Cytogenetics of pediatric central nervous system tumors. Cancer Genet Cytogenet 1996;91:13–27.
73.
Von Haken M, White E, Daneshvar-Shyesther L, et al: Molecular genetic analysis of chromosome arm 17p and chromosome arm 22q DNA sequences in sporadic pediatric ependymomas. Genes Chromosomes Cancer 1996;17:37–44.
74.
Hirose Y, Kunwar S, Bollen A, et al: Chromosomal abnormalities in ependymomas detected by comparative genomic hybridization. Proceedings of the American Association of Cancer Research, 1999, abstr 3540, p 40.
75.
Reyes-Mugica M, Chou M, Myint M, et al: Ependymomas in children: Histologic and DNA-flow cytometric study. Pediatr Pathol 1994;14:453–466.
76.
Kotylo P, Robertson P, Fineberg N, et al: Flow cytometric DNA analysis of pediatric intracranial ependymomas. Arch Pathol Lab Med 1997;121:1255–1258.
77.
Pierre-Khan A, Hirsch J, Roux F, et al: Intracranial ependymomas in childhood. Survival and functional results of 47 cases. Childs Brain 1983;10:145–156.
78.
Fokes E, Earle K: Ependymomas: Clinical and pathological aspects. J Neurosurg 1969;30:585–594.
79.
Healey E, Barnes P, Kupsky W, et al: The prognostic significance of postoperative residual tumor in ependymoma. Neurosurgery 1991;28:666–672.
80.
Papadopoulos D, Giri S, Evans R: Prognostic factors and management of intracranial ependymomas. Anticancer Res 1990;10:689–692.
81.
Vanuytsel L, Bessell E, Ashley S, et al: Intracranial ependymoma: Long-term results of a policy of surgery and radiotherapy. Int J Radiat Oncol Biol Phys 1992;23:313–319.
82.
Dailey A, McKhann GI, Berger M: The pathophysiology of oropharyngeal motor apraxia and mutism following posterior fossa tumor resection in children. J Neurosurg 1995;83:467–475.
83.
Culley D, Berger M, Shaw D, Geyer R: An analysis of factors determining the need for ventriculoperitoneal shunts following posterior fossa tumor surgery in children. Neurosurgery 1994;34:402–408.
84.
Rekate H, Grubb R, Aram D, et al: Muteness of cerebellar origin. Arch Neurol 1985;42:697–698.
85.
Erashin Y: Is splitting of the vermis responsible for cerebellar mutism? (Letter). Pediatr Neurosurg 1998;28:328.
86.
Kellog J, Piatt JJ: Resection of fourth ventricle tumors without splitting the vermis: The cerebellomedullary fissure approach. Pediatr Neurosurg 1997;27:28–33.
87.
Awaad Y, Allen J, Miller D, et al: Deferring adjuvant therapy for totally resected intracranial ependymoma. Pediatr Neurol 1996;14:216–219.
88.
Kun L, Kovnar E, Sanford R: Ependymomas in children. Pediatr Neurosci 1988;14:57–63.
89.
Goldwein J, Leahy J, Packer R, et al: Intracranial ependymomas in children. Int J Radiat Oncol Biol Phys 1990;19:1497–1502.
90.
Lyons M, PJ K: Posterior fossa ependymomas: Report of 30 cases and review of the literature. Neurosurgery 1991;28:659–665.
91.
Garrett P, Simpson W: Ependymomas: Results of radiation treatment. Int J Radiat Oncol Biol Phys 1983;9:1121–1124.
92.
Goldwein J, Corn B, Finlay J, et al: Is craniospinal irradiation required to cure children with malignant (anaplastic) intracranial ependymomas? Cancer 1991;67:2766–2771.
93.
Merchant T, Haida T, Ming-Hsien W: Anaplastic ependymoma: Treatment of pediatric patients with or without craniospinal radiation therapy. J Neurosurg 1997;86:943–949.
94.
Schild S, Nisi K, Scheithauer B: The results of radiotherapy for ependymomas: The Mayo Clinic experience. Int J Radiat Oncol Biol Phys 1998;42:953–958.
95.
Dunbar S, Tarbell N, Kooy H, et al: Stereotactic radiotherapy for pediatric and adult brain tumors: Preliminary report. Int J Radiat Oncol Biol Phys 1994;30:531–539.
96.
Aggarwal R, Yeung D, Kumar P, et al: Efficacy and feasibility of stereotactic radiosurgery in the primary management of unfavorable pediatric ependymoma. Radiother Oncol 1997;43:269–273.
97.
Grabb P, Lunsford L, Albright A, et al: Stereotactic radiosurgery for glial neoplasms of childhood. Neurosurgery 1996;38:696–701.
98.
Robertson P, Zeltzer P, Boyett J, et al: Survival and prognostic factors following radiation therapy and chemotherapy for ependymomas in children: A report of the Children’s Cancer Group. J Neurosurg 1998;88:695–703.
99.
Friedman H, Oakes W: The chemotherapy of posterior fossa tumors in childhood. J Neurooncol 1987;5:217–229.
100.
Bouffet EF, Foreman N: Chemotherapy for intracranial ependymomas. Childs Nerv Syst 1999;15:563–570.
101.
Duffner P, Horowitz M, Krischer J, et al: Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med 1993;328:1725–1731.
102.
Akyüz CE, Emir S, Akalan N, Söylemezoglu F, Kutluk T, Büyükpamukçu M: Intracranial ependymomas in childhood – A retrospective review of sixty-two children. Acta Oncol 2000;39:97–100.
103.
Timmermann B, Kortmann R, Kühl J, et al: Combined postoperative irradiation and chemotherapy for anaplastic ependymomas in childhood: Results of the German prospective trials HIT 88/89 and HIT 91. Int J Radiat Oncol Biol Phys 2000;46:287–295.
104.
Evans A, Anderson J, Lefkowitz-Boudreaux I, Finlay J: Adjuvant chemotherapy of childhood posterior fossa ependymoma: Cranio-spinal irradiation with or without adjuvant CCNU, vincristine and prednisone: A Children’s Cancer Group Study. Med Pediatr Oncol 1996;27:8–14.
105.
Goldwein J, Glauser T, Packer R, et al: Recurrent intracranial ependymomas in children survival, patterns of failure, and prognostic factors. Cancer 1990;66:557.
106.
Gaynon P, Ettinger L, Baum E, et al: Carboplatin in childhood brain tumors – A children’s cancer study group phase-II trial. Cancer 1990;66:2465.
107.
Lefkowitz I, Evans A, Sposto R, et al: Adjuvant chemotherapy of childhood posterior fossa ependymoma: Craniospinal radiation with or without CCNU, vincristine and prednisone (abstract). Pediatr Neurosci 1988;14:149.
108.
Geyer R, Zeltzer P, Finlay J, et al: Chemotherapy for infants with malignant brain tumors: Report of the Children’s Cancer Study Group trials CCG-921 and CCG-945. ASCO Annual Meeting, San Diego. Philadelphia, Saunders, 1992.
109.
Duffner P: Postoperative chemotherapy and delayed radiotherapy in infants with brain tumors: A pediatric oncology group study. Ann Neurol 1991;30:484.
110.
Gornet M, Buckner J, Marks R, et al: Chemotherapy for advanced CNS ependymoma. J Neurooncol 1999;45:61–67.
111.
Mason W, Goldman S, Yates A, et al: Survival following intensive chemotherapy with bone marrow reconstitution for children with recurrent intracranial ependymoma. J Neurooncol 1998;37:135–143.
112.
Grill J, Kalifa C, Doz F, et al: A high-dose busulfan-thiotepa combination followed by autologous bone marrow transplantation in childhood recurrent ependymoma. A phase-II study. Pediatr Neurosurg 1996;25:7–12.
113.
Kalifa C, Valteau D, Pizer B, et al: High-dose chemotherapy in childhood brain tumours. Childs Nerv Syst 1999;15:498–505.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.